Potent and selective LRRK2 inhibitor (IC50
values are 2.2, 6.6 and 47.7 nM for G2019S-mutant, wild-type and A2016T-mutant LRRK2, respectively). Selective for LRRK2 over a panel of 138 kinases. Brain penetrant and orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from Dana-Farber Cancer Institute.
Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor.
Hatcher et al.
ACS Med.Chem.Lett., 2015;6:584